LIVER CANCERS. FROM MECHANISMS TO MANAGEMENT

This book explores in detail the primary liver cancers of hepatocellular carcinoma and cholangiocarcinoma examining the pathogenesis of disease along with diagnosis and current management options together with exploration of future treatment strategies and areas of controversy. Furthermore, the book highlights management of the common secondary malignancies and touches on benign liver tumours and how to best manage these.
Written in a clear and didactic style, this volume includes summaries of the key learning points and questions so that the reader can gauge their knowledge and understanding.
This book is aimed to broaden the knowledge base of primary care physicians, general physicians along with specialists in hepatology, oncology and hepato-biliary surgery

Features
• Reviews liver cancer in a concise and comprehensive manner
• Written in a clear and didactic style which will be of use to both specialist and non-specialists
• Contains summary boxes to highlight the key points and simple questions so the reader can gauge their knowledge

Authors
• Dr Tim Cross, BMedSci (Hons), MB BS, MD, FRCP. Dr Cross qualified from St. Bartholomew’s hospital medical college in 1996. He undertook general gastroenterology training in North East London and hepatology training at Addenbrookes hospital, Cambridge, The Royal Free Hospital, University College Hospital and Kings College Hospital, London. He was a consultant at the South West Liver Unit, Plymouth UK before moving to the Royal Liverpool Hospital in 2012.
• Prof Daniel Palmer, BSc (Hons), MBChB, PhD, FRCP. Professor Palmer graduated from the University of Birmingham in 1995 and undertook his specialist training in Medical Oncology in the Birmingham Oncology Centre before taking the position of Cancer Research UK Clinician Scientist and Senior Lecturer, University of Liverpool. He took the North West Cancer Research Chair of Medical Oncology at the University of Liverpool in 2011. His specialist interests include development of novel therapies and clinical trials for hepatobiliary and pancreatic cancers.